Catalog No.
Product Name
Application
Product Information
Citations
-
Adrenergic Receptor Agonist
AR-08 is an agonist of the α2-adrenergic receptor, primarily involved in modulating neurotransmitter release and synaptic transmission. This compound exhibits key biological activity in the central nervous system, making it relevant for research into disorders such as attention deficit hyperactivity disorder (ADHD). AR-08 can be utilized to explore adrenergic signaling pathways and assess therapeutic potential in neuropsychiatric applications. -
Adrenergic Receptor Antagonist
Bometolol Hydrochloride is a selective beta-adrenergic receptor antagonist primarily targeting β1-adrenergic receptors. With its capacity to inhibit adrenergic signaling, it is employed in research focused on cardiovascular diseases, particularly in studies investigating heart rate regulation and blood pressure modulation. This compound provides valuable insights into the mechanisms underlying cardiac function and the therapeutic potential for hypertension and related disorders. -
Adrenergic Receptor Antagonist
Falintolol, (Z)- is a selective β-adrenergic receptor antagonist known for its unique oxime functionality. This compound exhibits key biological activity by blocking β-adrenergic signaling pathways, making it valuable for studies in cardiovascular research and the regulation of metabolic processes. Its ability to interact with adrenergic receptors provides insights into the pharmacological modulation of various physiological responses. -
Adrenergic Receptor Antagonist
Phentolamine Analogue 1 is a nonselective alpha-adrenergic receptor antagonist. This compound demonstrates significant inhibitory activity against adrenergic signaling pathways, making it a valuable tool for studying cardiovascular regulation and neuropharmacology. Its application in research may include investigations into blood pressure modulation, vasodilation mechanisms, and the effects of adrenergic receptor blockade in various biological systems. -
Amylin Receptor Antagonist
AC 187 is a potent and orally bioavailable antagonist of the amylin receptor, exhibiting an IC50 of 0.48 nM and a Ki of 0.275 nM. This compound demonstrates selectivity for the amylin receptor over calcitonin and CGRP receptors. AC 187 has been shown to possess neuroprotective effects, making it a valuable tool for research in neurodegenerative diseases and metabolic disorders. -
Amylin Receptor/Calcitonin Receptor/CGRP Receptor Agonit
Davalintide is a potent agonist of the amylin receptor, calcitonin receptor, and calcitonin gene-related peptide (CGRP) receptor, demonstrating high affinity with IC50 values of 0.04 nM, 0.06 nM, and 3.1 nM, respectively. It effectively stimulates cyclic AMP production via the calcitonin receptor, with an EC50 of 1.4 nM. Davalintide has been shown to regulate blood glucose levels and body weight through mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and suppressing food intake. This peptide is valuable for research applications focused on obesity and diabetes management. -
GLP-1/Amylin Agonist
Zenagamtide is a GLP-1 and amylin receptor agonist that acts as a triple agonist also targeting the calcitonin receptor. It is a peptide comprising 68 amino acids and is capable of crossing the blood-brain barrier, making it effective in modulating appetite and reducing energy intake. Research suggests that Zenagamtide may lead to improvements in body weight, waist circumference, glycated hemoglobin, and lipid profiles, while also enhancing insulin sensitivity and ameliorating features of metabolic dysfunction-associated steatotic liver disease (MASLD). Its biological activity makes it valuable for investigating conditions related to overweight, obesity, and insulin resistance. -
Angiotensin Receptor
CNP-38 is a C-type natriuretic peptide that primarily targets the angiotensin receptor. This compound exhibits potent biological activity associated with vasodilation and blood pressure regulation. CNP-38 is valuable in research applications related to cardiovascular physiology and potential therapeutic strategies for hypertension and heart failure. -
Angiotensin Receptor
Angiotensin II (5-8), human is a biologically active C-terminal fragment of the vasoconstrictor angiotensin II, targeting the angiotensin II type 1 (AT1) receptor. This fragment activates G protein-coupled receptors (GPCRs) in vascular smooth muscle cells, leading to increased intracellular calcium levels and vasoconstriction. Additionally, Angiotensin II (5-8) influences renal function by interacting with the Na+/H+ exchanger in the proximal tubules, making it a valuable tool for research in cardiovascular and renal physiology. -
Angiotensin Receptor Antagonist
Valsartan-d9 is a deuterated form of valsartan, an angiotensin II receptor antagonist. This compound is primarily used in research related to hypertension and heart failure, facilitating investigations into the mechanisms of blood pressure regulation and cardiovascular health. Its unique isotopic labeling allows for advanced tracking and analysis in pharmacokinetic and metabolic studies. -
Angiotensin Receptor Antagonist
Olmesartan lactone impurity is a cyclic ester derivative associated with Olmesartan, an angiotensin II receptor (AT1R) antagonist. This impurity can serve as a reference standard in analytical studies and quality control processes for assessing Olmesartan purity. Its relevance in hypertension research underscores its importance in understanding the pharmacological profiles of angiotensin receptor modulators. -
Angiotensin Receptor Activator
DuP-532 is an angiotensin type 1 receptor antagonist that plays a crucial role in the management of hypertension and heart failure. This compound is capable of reacting with various aryl and heteroaryl halides to yield perfluoroalkyl(hetero)arenes efficiently. Additionally, computational studies indicate that the introduction of a secondary phenyl ring ligand can decrease the energy barrier for the decarboxylation of perfluorocarboxylates, facilitating the perfluoroalkylation process. -
Angiotensin Receptor Inhibitor
H-Val-Pro-Pro-OH TFA is an inhibitor of Angiotensin I converting enzyme (ACE), demonstrating an IC50 of 9 μM. This milk-derived proline peptide derivative is utilized in research applications focused on cardiovascular biology and hypertension. Its role in modulating the renin-angiotensin system makes it a valuable tool for studying the effects of ACE inhibition in various physiological and pathological contexts. -
Angiotensin Receptor Antagonist
Dehydro Olmesartan is a potent angiotensin II receptor (AT1R) antagonist, derived from Olmesartan. This compound exhibits significant antihypertensive activity, making it valuable for research focused on hypertension and cardiovascular diseases. Its ability to inhibit AT1R provides insights into the mechanisms underlying blood pressure regulation and potential therapeutic strategies. -
Angiotensin Receptor Antagonist
Tetrahydro Aldosterone is an angiotensin receptor antagonist that effectively inhibits adrenal angiotensin II receptors, demonstrating an IC50 of 10 μM. This compound is utilized in research to investigate the role of the renin-angiotensin system in cardiovascular and renal physiology. Its application extends to exploring mechanisms of hypertension and related disorders. -
Angiotensin II Analogue
[Sar1, Ile8]-Angiotensin II is a synthetic analogue of angiotensin II that primarily targets angiotensin receptors, inducing various physiological effects. This peptide is known to elicit vasoconstriction in normal arterial tissue and promotes hypertrophic or hyperplastic responses in cultured vascular smooth muscle cells and diseased vasculature. Its versatile biological activity makes it valuable in research applications focused on cardiovascular physiology, vascular remodeling, and related pathophysiological processes. -
Angiotensin Receptor
ZD 7155 is a selective antagonist of the angiotensin II type 1 receptor (AT1R), known for its effects on renal function. Research indicates that ZD 7155 modulates electrolyte excretion, particularly increasing the excretion of sodium, potassium, and chloride in postnatal lamb models. In studies involving 6-week-old lambs, pretreatment with ZD 7155 significantly enhanced urine flow rates and free water clearance, while also reducing urine osmolality. This compound is essential for investigating the role of AT1R in renal physiology and the interactions with nitric oxide in electrolyte regulation. -
Angiotensin Receptor Antagonist
Olmesartan medoxomil impurity C is a chemical impurity related to Olmesartan medoxomil, a selective antagonist of the angiotensin AT1 receptor. It exhibits inhibitory activity with an IC50 value of 66.2 μM, making it relevant for studies focused on hypertension and cardiovascular disorders. This impurity can serve as a reference standard in the characterization and analytical assessment of Olmesartan medoxomil formulations in research applications. -
Angiotensin Receptor Activator
Mitolactol, an angiotensin receptor activator, exhibits effective inhibition of angiotensin-converting enzyme (ACE) with an IC50 value of 1.4 × 10 M. This compound is known for its ability to suppress the pressor response to angiotensin I when administered intravenously at a dose of 0.3 mg/kg in rat models. Mitolactol is of interest for research focusing on cardiovascular physiology, hypertension, and related therapeutic applications. -
Angiotensin II Analog
Nva-VYIHPF is an analog of Angiotensin II that selectively targets the angiotensin receptor type 1 (AT1). This compound exhibits potent binding affinity and biological activity, making it valuable for studying the renin-angiotensin system. Researchers can utilize Nva-VYIHPF in various applications, including cardiovascular research, hypertension studies, and investigations into cellular signaling pathways influenced by angiotensin II. -
Angiotensin Receptor
[Tyr(P)4] Angiotensin II is a phosphopeptide analog of angiotensin II that primarily targets the angiotensin receptor. It is known to induce vasoconstriction in normal arterial smooth muscle and promote cellular hypertrophy or hyperplasia in cultured cells and diseased vascular tissues. This compound is valuable for research into cardiovascular physiology, hypertension, and related pathologies. -
Antiarrhythmic Compounds
BW A256C is an antiarrhythmic compound that acts as both an angiotensin-converting enzyme inhibitor and a beta-adrenergic receptor blocker. This dual action contributes to its effectiveness in modulating cardiovascular responses and stabilizing cardiac rhythm. BW A256C serves as a valuable tool for research focused on cardiac arrhythmias and related cardiovascular conditions. -
Angiotensin Receptor Agonist
Angiotensin II (1-4), human is an endogenous peptide that functions as an agonist for the angiotensin receptor. It primarily binds to the AT II type 1 (AT1) receptor, activating GPCRs in vascular smooth muscle cells, which leads to an increase in intracellular calcium levels. Additionally, Angiotensin II (1-4) influences the sodium/hydrogen exchanger in the proximal tubules of the kidney, playing a critical role in regulating blood pressure and fluid balance. This peptide is valuable for research applications related to cardiovascular function and renal physiology. -
Angiotensin Receptor Antagonist
Saprisartan potassium is a selective angiotensin II receptor type 1 (AT1) antagonist that exhibits long-lasting effects. It demonstrates notable hypotensive activity by inhibiting the AT1 receptor, which plays a crucial role in the regulation of blood pressure and fluid balance. This compound is primarily utilized in research applications related to cardiovascular physiology, hypertension studies, and the investigation of renin-angiotensin system modulation. -
Angiotensin Receptor Agonist
Angiotensin II (3-8), human is a selective agonist of the angiotensin AT1 receptor. Though it exhibits reduced efficacy compared to its full-length counterpart, it serves as a valuable tool in studies investigating angiotensin receptor signaling pathways. This compound is utilized in cardiovascular research and the exploration of blood pressure regulation mechanisms. -
Angiotensin Receptor Antagonist
Saprisartan is a selective angiotensin II type 1 (AT1) receptor antagonist known for its long-acting effects and low receptor dissociation kinetics. It effectively inhibits the binding of angiotensin II, resulting in vasodilation and a decrease in blood pressure. This compound is utilized in research to explore its potential benefits in treating hypertension and related cardiovascular conditions. -
Angiotensin Receptor Activator
AZ11657312 is an angiotensin receptor activator that enhances renal medullary perfusion in the context of angiotensin II treatment. This compound significantly improves tissue oxygenation by inhibiting P2X7 receptor activity, particularly in underoxygenated regions of the kidney. AZ11657312 has been shown to increase sodium excretion dramatically, up to sixfold, while also normalizing blood pressure. Its unique mechanism and biological activity make it a valuable tool for studying renal function and hypertension. -
Angiotensin Receptor Activator
BRL-36378 is an angiotensin receptor activator that modulates the activity of angiotensin-converting enzyme. This compound exhibits significant biological activity, making it valuable for research applications focused on cardiovascular and renal systems. Additionally, BRL-36378 serves as a useful tool in ligand-based virtual screening for the identification of novel lead compounds suitable for chemical optimization. -
Angiotensin Receptor Antagonist
L162441 is an antagonist of the angiotensin type 1 receptor. It selectively inhibits receptor activation, leading to decreased vasoconstriction and reduced blood pressure. This compound is primarily utilized in cardiovascular research to investigate the role of angiotensin signaling in hypertension and other related disorders. -
Angiotensin Receptor Antagonist
LY285434 is a potent angiotensin II receptor antagonist that selectively inhibits the binding of angiotensin II to its receptors. This compound demonstrates significant biological activity in regulating blood pressure and fluid balance, making it a valuable tool for research in cardiovascular physiology and related disorders. Its application includes studying the role of the renin-angiotensin system in hypertension and exploring potential therapeutic strategies for related diseases. -
Angiotensin Receptor Antagonist
A81988 is a potent, competitive antagonist that targets angiotensin AT1 receptors. This non-peptidic compound demonstrates significant inhibition of receptor activity, making it a valuable tool for studying angiotensin signaling pathways. A81988 is applicable in research focused on cardiovascular disorders and hypertension, offering insights into therapeutic interventions for related conditions. -
CXCR6 Antagonist
ML339 is a selective antagonist of the CXCR6 receptor, displaying an IC50 of 140 nM. It inhibits β-arrestin recruitment and the cAMP signaling pathway induced by CXCL16 in human CXCR6, with IC50 values of 0.3 μM and 1.4 μM, respectively. While exhibiting reduced efficacy against mouse CXCR6 with an IC50 of 18 μM, ML339 demonstrates no significant inhibition of CXCR5, CXCR4, or the apelin receptor (APJ), with IC50 values exceeding 79 μM. This compound shows promise for advancing research focused on prostate cancer. -
CXCR Inhibitor
ALX 40-4C is a small peptide inhibitor targeting the chemokine receptor CXCR4. It effectively prevents the binding of SDF-1 to CXCR4 with a Ki of 1 μM, thereby inhibiting the replication of X4 strains of HIV-1. Additionally, ALX 40-4C Trifluoroacetate serves as an antagonist of the APJ receptor, exhibiting an IC50 value of 2.9 μM. This dual activity makes ALX 40-4C a valuable tool for research in HIV-1 studies and chemokine receptor signaling pathways. -
CB1 Antagonist
Monlunabant is a selective antagonist of the cannabinoid receptor 1 (CB1) with an inhibitory constant (Ki) of 0.3 nM for human CB1 receptors, and 613 nM for human CB2 receptors. This compound demonstrates potent activity in modulating cannabinoid signaling pathways, making it a valuable tool for researching the roles of CB1 in various physiological processes. Its applications include the exploration of metabolic disorders, neurodegenerative diseases, and potential therapeutic interventions involving the endocannabinoid system. -
GLP-1R Agonist
CT-996 is an orally active GLP-1 receptor (GLP-1R) agonist with an EC50 of 0.49 nM, modulating glucose metabolism through its effects on β-arrestin recruitment and receptor internalization. This compound significantly lowers postprandial blood glucose levels in mice engineered to express human GLP-1 receptors and enhances glucose-stimulated insulin secretion (GSIS) in obese monkey models during intravenous glucose challenges. CT-996 serves as a valuable tool for research focused on type 2 diabetes and obesity. -
CXCR Receptor Inhibitor
SCH-900875 is a selective inhibitor of the CXCR3 receptor, known for its oral bioavailability and ability to penetrate the blood-brain barrier. By binding to CXCR3, it effectively prevents the interaction of ligands CXCL9, CXCL10, and CXCL11, thereby inhibiting downstream G protein and β-arrestin signaling pathways, which reduces inflammatory cell migration. This compound holds potential for investigating various autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, as well as inflammatory conditions like psoriasis and inflammatory bowel disease. -
CB1R Positive Allosteric Modulator
CB1R Allosteric Modulator 3 is a positive allosteric modulator targeting the CB1 receptor. It exhibits potent inhibition of cyclic AMP (cAMP) and β-Arrestin with EC50 values of 0.018 μM and 1.241 μM, respectively. This compound is valuable for research applications focused on understanding cannabinoid receptor signaling and its implications in various physiological processes. -
Bombesin Receptor Antagonist
Bombesin receptor antagonist-1 functions as a selective antagonist for the bombesin receptors, exhibiting Ki values of 0.17 nM for the neurotide B (NMB) receptor and 20 nM for the gastrin-releasing peptide (GRP) receptor. This compound is instrumental in the investigation of various pathophysiological conditions, including cancer, depression, and eating disorders. Its precise modulation of bombesin receptors provides valuable insights into receptor signaling pathways and potential therapeutic targets in related diseases. -
Bombesin Receptor Antagonist
Kuwanon H is a flavonoid isolated from Morus alba that functions as a potent non-peptide antagonist of bombesin receptors. It selectively inhibits the binding of gastrin-releasing peptide to GRP-preferring receptors, exhibiting a Ki value of 290 nM in cellular assays. This compound is valuable for research applications involving cancer biology and neurobiology, particularly in studies focusing on receptor signaling pathways and their role in tumor growth and metastasis. -
GRP/BN receptor Antagonist
BIM-26226 is a selective antagonist of the gastrin-releasing peptide receptor (GRPR) and bombesin (BN) receptor, exhibiting an IC50 of 6 nM. This compound effectively inhibits BN- or GRP-stimulated amylase release with IC50 values of 0.3 nM and 0.2 nM, respectively. BIM-26226 shows high specificity for the GRP-preferring BN receptor subtype and does not interfere with the GRP receptor system. Additionally, it can induce the synthesis of somatostatin receptors while demonstrating no significant effect on tumor growth, making it valuable for research into neuropeptide signaling and related biological pathways. -
GRP/Bombesin Receptor 2 Antagonist
ICI 216140 is a potent GRP/bombesin receptor 2 antagonist with an IC50 value of 2 nM. This compound effectively inhibits Bombesin-stimulated pancreatic amylase secretion and mitigates Bombesin-induced increases in blood pressure. ICI 216140 is valuable for research into the physiological roles of bombesin receptors and their implications in various pathophysiological conditions. -
Bombesin Receptor Agonist
Ranatensin is an undecapeptide that acts as an agonist of the bombesin receptor. Isolated from amphibian skin, particularly from the frog Rana pipiens, ranatensin plays a crucial role in regulating blood pressure dynamics. It exhibits distinct biological activity without cross-tachyphylaxis with other peptides such as angiotensin amide, bradykinin, or norepinephrine, making it a valuable tool for cardiovascular research applications. -
Bombesin Receptor Antagonist
[D-Phe12,Leu14]-Bombesin is a potent antagonist of the Bombesin receptor. This compound exhibits key biological activity in blocking Bombesin-mediated signaling pathways, making it valuable for cancer research. It is utilized in studies focused on tumor growth and proliferation, particularly in neuroendocrine tumors and related conditions. -
Bombesin Receptor Antagonist
[D-Phe12]-Bombesin is a bombesin receptor antagonist with a Ki value of 4.7 μM. This compound effectively inhibits bombesin-induced amylase release, exhibiting an IC50 of 4 μM. It is valuable for research applications exploring the role of bombesin receptors in physiological and pathological processes, particularly in studies related to neuroendocrine signaling and cancer biology. -
Bombesin Receptor Ligand
GRP (14-27) is a bombesin receptor ligand derived from human, porcine, and canine sources. This peptide displays specific binding properties to bombesin receptors, which is inhibited by guanosine triphosphate (GTP) and guanosine diphosphate (GDP), indicating a competitive mechanism of action. GRP (14-27) is useful in research applications focused on neuropeptide signaling and receptor interactions. -
Bombesin Receptor Agonist
[D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) is a synthetic peptide that acts as a non-selective agonist for bombesin receptors. It exhibits favorable pEC50 values of 8.06 for the BB1 receptor, 8.69 for BB2, and 6.71 for BB3. This compound is valuable for research into various pathologies associated with bombesin receptors, including cancer and neurological disorders. -
Cannabinoid Receptor Agonist
2-Arachidonoylglycerol is a potent agonist of cannabinoid receptors, primarily targeting CB1 and CB2 receptors in the central nervous system. It plays a crucial role in various physiological processes, including pain modulation, appetite control, and neuroprotection. 2-Arachidonoylglycerol is widely used in research applications investigating the endocannabinoid system and its implications in neurobiology, pharmacology, and therapeutic development. -
Biochemical Assay Reagent
ACEA (arachidonyl-2'-chloroacetamide) is a synthetic compound that acts as an agonist of the cannabinoid receptor CB1. It modulates the endocannabinoid system, influencing physiological processes including appetite regulation, pain perception, mood, and memory. This biochemical assay reagent is essential for research exploring the pharmacological effects and therapeutic potential of cannabinoid signaling. -
Insecticide
S-Methoprene is an insect juvenile hormone analog that functions as an effective insecticide by disrupting the transformation from pupa to adult stage in insects. Additionally, S-Methoprene acts as a ligand for the CB(1) receptor, inhibiting the binding of the CB1 receptor antagonist [3H]CP-55940 with an IC50 of 19.31 μM. This compound is valuable in research applications focused on pest control and the mechanisms of cannabinoid receptor interactions. -
PDK Inhibitor, CB1/CB2 Agonist
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor, demonstrating an IC50 value of 9.5 μM. It effectively lowers blood glucose levels in diabetic mouse models. Additionally, Leelamine acts as a weak agonist of cannabinoid receptors CB1 and CB2. Its biological activity includes a reduction in mitotic activity and prostate-specific antigen expression, as well as the induction of apoptosis in cancer cells, making it a valuable tool for cancer research and metabolic studies.
